The obesity epidemic in the US continues unabated. The elevated risk for severe disease and death from COVID-19 associated with obesity and its comorbidities underscores the urgency to develop and implement effective prevention and treatment strategies. Multicomponent behavior-based weight management interventions are recommended for adults with obesity; however, some patients do not respond to even the highest-quality programs. Medications are well-accepted in the management of other disorders that potentially respond to dietary interventions, such as the use of statin drugs for hypercholesterolemia. However, many clinicians are hesitant to prescribe, payers are hesitant to reimburse for, and patients are hesitant to use antiobesity medications.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Yanovski SZ, Yanovski JA. Progress in Pharmacotherapy for Obesity. JAMA. 2021;326(2):129–130. doi:10.1001/jama.2021.9486
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: